Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity
暂无分享,去创建一个
I. Rusyn | J. Corton | K. Guyton | Ruth Roberts | Martyn T. Smith | S. Khetani | N. Kaplowitz | Xabier Arzuaga | R. Cattley | P. Godoy | S. Ferguson | R. Roth | R. Roberts | S. Ferguson
[1] C. Bocca,et al. Liver fibrogenesis: UN update on established and emerging basic concepts. , 2020, Archives of biochemistry and biophysics.
[2] Sijin Liu,et al. TCDD promotes liver fibrosis through disordering systemic and hepatic iron homeostasis. , 2020, Journal of hazardous materials.
[3] Z. Younossi,et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD , 2020, Hepatology.
[4] J. Little,et al. Concordance between sites of tumor development in humans and in experimental animals for 111 agents that are carcinogenic to humans , 2019, Journal of toxicology and environmental health. Part B, Critical reviews.
[5] N. Kang. Mechanotransduction in Liver Diseases , 2019, Seminars in Liver Disease.
[6] R. Schwabe,et al. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. , 2019, Gastroenterology.
[7] R. Prough,et al. Mechanisms of Environmental Contributions to Fatty Liver Disease , 2019, Current Environmental Health Reports.
[8] P. Kamath,et al. Burden of liver diseases in the world. , 2019, Journal of hepatology.
[9] R. Yang,et al. DAMPs and sterile inflammation in drug hepatotoxicity , 2018, Hepatology International.
[10] T. Luedde,et al. Apoptosis and necroptosis in the liver: a matter of life and death , 2018, Nature Reviews Gastroenterology & Hepatology.
[11] N. Kaplowitz,et al. New insights into the role and mechanism of c‐Jun‐N‐terminal kinase signaling in the pathobiology of liver diseases , 2018, Hepatology.
[12] Ivan Rusyn,et al. Application of the key characteristics of carcinogens in cancer hazard identification , 2018, Carcinogenesis.
[13] M. Fielden,et al. Modernizing Human Cancer Risk Assessment of Therapeutics. , 2017, Trends in pharmacological sciences.
[14] T. Monticello,et al. Current nonclinical testing paradigm enables safe entry to First‐In‐Human clinical trials: The IQ consortium nonclinical to clinical translational database , 2017, Toxicology and applied pharmacology.
[15] G. Kullak-Ublick,et al. Drug-induced bile duct injury. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[16] N. Kaplowitz,et al. Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis , 2017, International journal of molecular sciences.
[17] Jiezhun Gu,et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements , 2017, Hepatology.
[18] E. Bjornsson. Drug-induced liver injury due to antibiotics , 2017 .
[19] B. K. Park,et al. Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients. , 2016, Chemical research in toxicology.
[20] Marlene Ågerstrand,et al. Implementing systematic review techniques in chemical risk assessment: Challenges, opportunities and recommendations. , 2016, Environment international.
[21] Ivan Rusyn,et al. Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis , 2015, Environmental health perspectives.
[22] C. McClain,et al. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences , 2015, Cellular and molecular gastroenterology and hepatology.
[23] T. Luedde,et al. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. , 2014, Gastroenterology.
[24] D. Tweedie,et al. The Role of Transporters in Toxicity and Disease , 2014, Drug Metabolism and Disposition.
[25] Mitchell R. McGill,et al. Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans. , 2014, Toxicology and applied pharmacology.
[26] T. Starr,et al. Mode of action and dose–response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study , 2014, Critical reviews in toxicology.
[27] G. Gores,et al. Apoptosis and necrosis in the liver. , 2013, Comprehensive Physiology.
[28] K.,et al. Toxicant-associated Steatohepatitis , 2013, Toxicologic pathology.
[29] Michael Karin,et al. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. , 2012, Gastroenterology.
[30] J. Manautou,et al. Molecular mechanisms underlying chemical liver injury , 2012, Expert Reviews in Molecular Medicine.
[31] Mitchell R. McGill,et al. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity , 2012, Drug metabolism reviews.
[32] J. Boyer,et al. Drug‐induced cholestasis , 2011, Hepatology.
[33] B. Fromenty,et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.
[34] J. Ward,et al. Hepatic Enzyme Induction , 2010, Toxicologic pathology.
[35] D. Adams,et al. Mechanisms of immune-mediated liver injury. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[36] J. Ross,et al. Liver Development, Regeneration, and Carcinogenesis , 2010, Journal of biomedicine & biotechnology.
[37] K. Zatloukal,et al. The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice , 2009, Hepatology.
[38] Ivan Rusyn,et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[39] N. Kaplowitz,et al. ER stress: can the liver cope? , 2006, Journal of hepatology.
[40] N. Kaplowitz,et al. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. , 2005, Toxicology and applied pharmacology.
[41] Terry S Peters,et al. Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials? , 2005, Toxicologic pathology.
[42] Martyn T. Smith,et al. Mechanisms of troglitazone hepatotoxicity. , 2003, Chemical research in toxicology.
[43] G. Gores,et al. Mechanisms of hepatotoxicity. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[44] G. Orphanides,et al. Role of cytokines in non-genotoxic hepatocarcinogenesis: cause or effect? , 2001, Toxicology letters.
[45] Cody L. Wilson,et al. Mechanisms of Ligand-Induced Aryl Hydrocarbon Receptor-Mediated Biochemical and Toxic Responses , 1998, Toxicologic pathology.
[46] Steven D. Cohen,et al. Selective protein covalent binding and target organ toxicity. , 1997, Toxicology and applied pharmacology.
[47] D. Parke. Mechanisms and consequences of the induction of microsomal enzymes of mammalian liver. , 1972, The Biochemical journal.
[48] Ellen Mantus,et al. Using 21st Century Science to Improve Risk-Related Evaluations , 2017 .
[49] Ivan Rusyn,et al. In vitro models for liver toxicity testing. , 2013, Toxicology research.
[50] G. Gores,et al. Liver cell necrosis: cellular mechanisms and clinical implications. , 1995, Gastroenterology.